Sep 4, 2024 · CC BY-NC .0 Licence É Copyright 202 EM É November 2024 É Dermatology 95 Current Landscape and Emerging Therapies in Hair Loss Treatment for Androgenetic Alopecia ...
EMJ | Elevating the quality of healthcare globally
This phase 1–2, randomised, double-blind, placebo-controlled trial enrolled 130 patients aged 18 or older with confirmed sickle cell disease.
Ultrasound Renal Denervation Shows Long-Term Success in …
Nov 21, 2024 · A groundbreaking study has demonstrated the long-term safety and efficacy of ultrasound renal sympathetic denervation (uRDN) for managing resistant hypertension, with results from the ACHIEVE study showing sustained blood pressure (BP) reduction and decreased reliance on medication over eight years.. The prospective study followed 27 patients from an original cohort of 96 who underwent uRDN.
Oct 4, 2024 · 2 Factor XI/XIa Inhibitors: What We Now Know Interview Interview Summary The emerging class of agents targeting factor XI/XIa offers the paradigm-
Global Diabetes Cases Surpass 800 Million, Highlighting Treatment ...
Nov 21, 2024 · A GROUNDBREAKING study led by Imperial College London, UK has revealed that over 800 million adults worldwide now live with Type 1 or Type 2 diabetes.Researchers explain that global diabetes rates have doubled from 7% in 1990 to 14% in 2022, driven largely by rising cases in low- and middle-income countries (LMICs).
May 2, 2024 · Abbreviations: AML: acute myeloid leukemia; CCUS: clonal cytopenia of undetermined significance; del: deletion; EB: excess blasts; FISH: fluorescence in situ ...
What does Trump’s win mean for pharma? - emjreviews.com
Nov 6, 2024 · Words by Jade Williams. With Donald Trump securing a second presidential term and his party taking control of the Senate, the US pharmaceutical industry enters a period that could bring both continuity and change over the next four years.
A Guide to Chronic Hand Eczema: What Healthcare Professionals Should Know This infographic was funded by LEO Pharma. Dermatol AMJ. 2024. https://doi.org/10.33590 ...
30 EM Ø September 2024 Ø Copyright 2024 EM Ø CC BY-NC 4.0 Licence Clinical Practice Insights for Hyperpigmentation Treatment Interview Summary Hyperpigmentation ...
Why EGFR Exon 21 L858R Mutations Should Be Treated Differently
BACKGROUND. EGFR gene mutations have been reported in 15–60% of non-small cell lung cancers (NSCLCs) with an important difference in prevalence between Eastern and Western populations. 1,2 The most common EGFR-activating mutations in NSCLC include in-frame deletions in exon 19 and a substitution in exon 21 (L858R) which account for 47% and 41%, respectively, of observed EGFR mutations in ...